L-Methionine
|
Basic information |
| Metabolite name | L-Methionine |
 | HMDB0000696 |
 |
C00073 |
 |
6137 |
| Synonyms | Methionine |
| No. of studies | 68 |
|
Basic information |
| Metabolite name | L-Methionine |
| HMDB0000696 |
|
C00073 |
|
6137 |
| Synonyms | Methionine |
| No. of studies | 68 |
|
Relationship between L-Methionine and depression (count: 68) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M002 | Type1 | CUMS group vs. control group | Brain | Sprague-Dawley rat | Up |
| Study M003 | Type1 | day 9 CUMS group vs. control group | Urine | Sprague-Dawley rat | Up |
| Study M018 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M018 | Type1 | CUMS group vs. control group | Brain | Sprague-Dawley rat | Down |
| Study M033 | Type3 | paroxetine group vs. control group | Hippocampus | DBA/2OlaHsd mouse | Down |
| Study M037 | Type2 | placebo treatment group four-week vs. baseline | Serum | Human | Up |
| Study M037 | Type2 | sertraline treatment group four-week vs. baseline | Serum | Human | Up |
| Study M051 | Type3 | fluoxetine group vs. control group | Astrocyte | Sprague-Dawley rat | Down |
| Study M061 | Type1 | depressed group vs. control group | Plasma | Human | Down |
| Study M065 | Type1 | depressed group vs. control group | Plasma | Human | Up |
| Study M066 | Type2 | CUMS + high dose of YHTA group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
| Study M066 | Type2 | CUMS + low dose of YHTA group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
| Study M066 | Type2 | CUMS + venlafaxine group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
| Study M066 | Type2 | CUMS + middle dose of YHTA group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
| Study M067 | Type1 | naturally-occurring depression group vs. control group | Serum | Cynomolgus monkey | Down |
| Study M076 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M076 | Type2 | CUMS + Anemarrhena saponins group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M076 | Type2 | CUMS + Lilium saponins group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M084 | Type1 | melancholic depressed group vs. control group | Plasma | Human | Up |
| Study M087 | Type2 | ketamine group 2-h vs. baseline | Plasma | Human | Down |
| Study M1023 | Type1 | CRS group vs. control group | Faece | C57BL/6 J mouse | Up |
| Study M104 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M104 | Type2 | CUMS + ZB group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M104 | Type2 | CUMS + BH group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M1053 | Type1 | CUMS group vs. control group | Liver | Sprague-Dawley rat | Up |
| Study M1053 | Type2 | CUMS + quercetin group vs. CUMS group | Liver | Sprague-Dawley rat | Down |
| Study M1056 | Type2 | maternal separation + beraprost group vs. maternal separation group | Serum | Sprague-Dawley rat | Down |
| Study M1057 | Type1 | depression group vs. control group | Serum | Human | Up |
| Study M1072 | Type1 | CUMS group vs. control group | Plasma | Cynomolgus monkey | Down |
| Study M1091 | Type1 | CMS vulnerable group vs. control group | Ventral hippocampus | Wistar rat | Up |
| Study M1092 | Type3 | venlafaxine group vs. control group | Ventral hippocampus | Wistar rat | Up |
| Study M1093 | Type1 | CSDS group vs. control group | Serum | C57BL/6N mouse | Down |
| Study M114 | Type3 | venlafaxine group vs. control group | Astrocyte | Sprague-Dawley rat | Down |
| Study M1143 | Type1 | MDD group vs. control group | Plasma | Human | Down |
| Study M115 | Type1 | MDD group vs. control group | Plasma | Human | Down |
| Study M119 | Type1 | LH group vs. control group | Prefrontal cortex | Sprague-Dawley rat | Down |
| Study M131 | Type1 | SD group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M180 | Type1 | dMDD group vs. control group | Plasma | Human | Down |
| Study M207 | Type1 | depressed group vs. control group | Faece | Kunming mouse | Down |
| Study M208 | Type1 | GCI model group vs. control group | Hippocampus | ICR mouse | Down |
| Study M458 | Type1 | depression group vs. control group | Plasma | Human | Down |
| Study M463 | Type3 | DG group vs. control group | Prefrontal cortex | C57BL/6J mouse | Up |
| Study M510 | Type1 | HSD group vs. control group | Serum | Human | Down |
| Study M522 | Type1 | CUMS group vs. control group | Prefrontal cortex | Sprague-Dawley rat | Unknown |
| Study M539 | Type2 | LPS+ Dl-3-n-butylphthalide group vs. LPS group | Hippocampus | Sprague-Dawley rat | Down |
| Study M540 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M541 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M541 | Type2 | CUMS + venlafaxine group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M541 | Type2 | CUMS + high dose of AS group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M555 | Type1 | FMT group vs. control group | Liver | Sprague-Dawley rat | Down |
| Study M573 | Type1 | CSDS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M592 | Type1 | CUMS group vs. control group, NMR | Liver | Sprague-Dawley rat | Up |
| Study M610 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M611 | Type1 | LPS group vs. control group | Serum | Sprague-Dawley rat | Unknown |
| Study M631 | Type1 | CUMS group vs. control group | Serum | Kunming mouse | Down |
| Study M632 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Unknown |
| Study M642 | Type1 | SDS group vs. control group | Faece | Sprague-Dawley rat | Down |
| Study M680 | Type2 | 5-fluorouracil + FMT group vs. 5-fluorouracil + sham FMT group | Prefrontal cortex | Sprague-Dawley rat | Down |
| Study M722 | Type1 | CUMS-transferred group vs. control-transferred group | Serum | C57BL/6J mouse | Down |
| Study M749 | Type1 | CUMS group vs. control group | Plasma | Cynomolgus monkey | Down |
| Study M771 | Type1 | CSDS group vs. control group | Faece | C57BL/6J mouse | Up |
| Study M779 | Type1 | depression group vs. control group | Plasma | Human | Up |
| Study M791 | Type1 | CUMS group vs. control group | Cecum | Sprague-Dawley rat | Down |
| Study M806 | Type1 | CUMS group vs. control group | Urine | C57BL/6 mouse | Down |
| Study M806 | Type2 | corticosterone + Gleditsiae spina group vs. corticosterone group | Urine | C57BL/6 mouse | Up |
| Study M806 | Type2 | corticosterone + taxifolin spina group vs. corticosterone group | Urine | C57BL/6 mouse | Up |
| Study M828 | Type2 | ultrasonic radiation + intraperitoneally clomipramine group vs. ultrasonic radiation group | Frontal cortex | Wistar rat | Down |
| Study M828 | Type2 | ultrasonic radiation + intranasally clomipramine group vs. ultrasonic radiation group | Frontal cortex | Wistar rat | Down |
| Study M828 | Type2 | ultrasonic radiation + intranasally clomipramine group vs. ultrasonic radiation group | Hippocampus | Wistar rat | Up |
| Study M836 | Type1 | CRS group vs. control group | Serum | C57BL/6 mouse | Down |
| Study M839 | Type1 | MDD group vs. control group | Plasma | Human | Down |
| Study M844 | Type1 | CORT group vs. control group | PC12 cell | Rat | Up |
| Study M877 | Type1 | depressed COPD group vs. COPD group | Plasma | Human | Down |
| Study M882 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M908 | Type3 | post-ketamine treatment vs. baseline | Plasma | Human | Up |
| Study M924 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M927 | Type1 | CUMS group vs. control group | Brain | Sprague-Dawley rat | Down |
| Study M927 | Type2 | CUMS + Zhi-zi-chi decoction group vs. CUMS group | Brain | Sprague-Dawley rat | Up |
| Study M928 | Type1 | CUMS group vs. control group | Faece | C57BL/6 mouse | Down |
| Study M947 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Up |
| Study M953 | Type1 | CRS group vs. control group | Faece | Sprague-Dawley rat | Up |
| Study M957 | Type1 | CSDS group vs. control group | Serum | C57BL/6 J mouse | Up |
| Study M957 | Type1 | CSDS group vs. control group | Hippocampus | C57BL/6 J mouse | Up |
| Study M962 | Type2 | 24h-post ketamine infusion vs. baseline | Plasma | Human | Up |
| Study M965 | Type1 | CUMS depression group vs. control group | Faece | Sprague-Dawley rat | Down |
| Study M981 | Type1 | Abeta oligomer group vs. control group | Serum | ICR mouse | Down |